Tags

Type your tag names separated by a space and hit enter

Terbinafine-induced subacute cutaneous lupus erythematosus.
Cutis. 2008 Feb; 81(2):156-7.C

Abstract

Terbinafine is a synthetic oral allylamine that is used for systemic treatment of microscopy- or culture-proven dermatophyte infections of skin and nails. It is normally well-tolerated and side effects include transient gastrointestinal symptoms and skin reactions that can occur in up to 2.3% of treated patients. Subacute cutaneous lupus erythematosus (SCLE) is a skin reaction that has been reported secondary to use of a variety of drugs. The number of reports of SCLE with terbinafine is limited. We demonstrate 2 patients in one dermatology clinic who presented with a predisposing autoimmune diathesis within 3 months of each other.

Authors+Show Affiliations

Wilford Hall Medical Center, Lackland Air Force Base, Lackland AFB, TX 78236-9908, USA. chivnor@pol.netNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

18441768

Citation

Hivnor, Chad M., et al. "Terbinafine-induced Subacute Cutaneous Lupus Erythematosus." Cutis, vol. 81, no. 2, 2008, pp. 156-7.
Hivnor CM, Hudkins ML, Bonner B. Terbinafine-induced subacute cutaneous lupus erythematosus. Cutis. 2008;81(2):156-7.
Hivnor, C. M., Hudkins, M. L., & Bonner, B. (2008). Terbinafine-induced subacute cutaneous lupus erythematosus. Cutis, 81(2), 156-7.
Hivnor CM, Hudkins ML, Bonner B. Terbinafine-induced Subacute Cutaneous Lupus Erythematosus. Cutis. 2008;81(2):156-7. PubMed PMID: 18441768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Terbinafine-induced subacute cutaneous lupus erythematosus. AU - Hivnor,Chad M, AU - Hudkins,Matthew L, AU - Bonner,Bert, PY - 2008/4/30/pubmed PY - 2008/7/4/medline PY - 2008/4/30/entrez SP - 156 EP - 7 JF - Cutis JO - Cutis VL - 81 IS - 2 N2 - Terbinafine is a synthetic oral allylamine that is used for systemic treatment of microscopy- or culture-proven dermatophyte infections of skin and nails. It is normally well-tolerated and side effects include transient gastrointestinal symptoms and skin reactions that can occur in up to 2.3% of treated patients. Subacute cutaneous lupus erythematosus (SCLE) is a skin reaction that has been reported secondary to use of a variety of drugs. The number of reports of SCLE with terbinafine is limited. We demonstrate 2 patients in one dermatology clinic who presented with a predisposing autoimmune diathesis within 3 months of each other. SN - 0011-4162 UR - https://www.unboundmedicine.com/medline/citation/18441768/Terbinafine_induced_subacute_cutaneous_lupus_erythematosus_ DB - PRIME DP - Unbound Medicine ER -